Evaluation of Circulating Tumor DNA as a Theranostic Marker in the Management of Glioblastomas.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

NA

Total Enrollment

19 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-03-09

Study Completion Date

2017-11-06

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Glioblastomas (GBM) are rare tumors of poor prognosis and their treatment is based on surgery followed by radiochemotherapy. Clinical and imaging evaluation is not always straightforward: the more or less complete surgery, the pseudo-progression after radiochemotherapy, the radionecrosis, the diagnosis of the relapse and the follow-up under anti-angiogenic can pose problems Clinicians and radiologists. Accessibility to a plasma tumor molecular marker would greatly facilitate the follow-up of these patients.

It is now established for many cancers that circulating tumor DNA (cTNA) has the same molecular abnormalities as those identified in the primary tumor cells. Numerous studies have shown the prognostic value and diagnosis of the exploration of cDNA.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of Tissue Samples From Patients With Glioma or Other Brain Tumors

NCT00967200

Central Nervous System Lymphoma

COMPLETED

Determination of Immune Phenotype in Glioblastoma Patients

NCT02751138

Glioblastoma Multiforme

COMPLETED

Evaluation of the Correlation Between Molecular Phenotype and Radiological Signature (by PET-scanner and MRI) of Incident WHO II and III Grade Gliomas.

NCT04461002

Glioma

COMPLETED

Image-derived Prediction of Response to Chemo-radiation in Glioblastoma

NCT02329795

Glioblastoma

TERMINATED

Radiomics for Prediction of Survival in GBM

NCT02666066

Glioblastoma Glioma Astrocytoma

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Glioblastoma Molecular Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients with glial tumor

Group Type OTHER

Correlation between molecular anomalies of the primary tumor and circulating tumor DNA

Intervention Type OTHER

The presence of a specific abnormality initially identified on the primary tumor and which can be quantified in the cDNA during the management will allow a better follow-up of the patient.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Correlation between molecular anomalies of the primary tumor and circulating tumor DNA

The presence of a specific abnormality initially identified on the primary tumor and which can be quantified in the cDNA during the management will allow a better follow-up of the patient.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with grade IV glial tumor (glioblastoma according to WHO criteria) for which an indication of surgical excision with radiochemotherapy was chosen at a specialized multidisciplinary meeting of neuro-oncology at the CHU Amiens-Picardy.
* Patients should:

* be able to be followed at the CHU of Amiens throughout their treatment,
* be at least 18 years of age,
* be informed (or trusted) of the conditions and objectives of the study,
* having given their free and informed consent in writing,
* have a life expectancy of more than 6 months,
* be affiliated to a social security scheme.

Exclusion Criteria

* Patients with recurrent tumors.
* Patients supported for another histology.
* Medical, psychological or social conditions that do not allow for proper understanding of the procedures inherent in the study.
* Patients under tutelage, curatorship.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No